Clinical trial
A Study of All-trans Retinoic Acid in the Treatment of Immune Thrombocytopenia
NCT04618328 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Study of All-trans Retinoic Acid in the Treatment of Immune Thrombocytopenia
- Lead sponsor
- Peking University People's Hospital
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- November 30, 2020
- Completion date
- October 31, 2021
- Enrollment
- 80 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
immune thrombocytopenia